WuXi AppTec Jumps to Near 5-Year High After H1 Profit Beats Estimates

Shares of WuXi AppTec (HK:2359) surged on Tuesday after the pharmaceutical research and manufacturing firm reported first-half earnings that significantly surpassed analyst expectations. The company's Hong Kong-listed stock jumped 10.7% to close at HK$180.30, its highest level since September 2021, strongly outperforming a slight decline in the broader Hang Seng Index.

Earnings Beat Fuels Rally

The investor enthusiasm followed the release of robust financial results for the first six months of the year. WuXi AppTec's performance was underpinned by strong, broad-based demand for its services.

• Net Profit: Attributable net profit rose 33.7% year-over-year to 11.08 billion yuan.
• Revenue: Total revenue climbed 38.9% from the prior-year period to 28.9 billion yuan.

Both top- and bottom-line figures came in well ahead of consensus market forecasts, according to the report from Investing.com.

U.S. Market and Peptides Drive Growth

Ad

Growth was particularly strong in the company's TIDES division, which handles the manufacturing of peptides, including GLP-1 agonists used in popular therapies for obesity and diabetes. Revenue from this high-growth segment increased by 44.3% to 7.26 billion yuan, cementing its role as a key business driver.

Despite ongoing geopolitical scrutiny of Chinese biotech firms, the U.S. remains WuXi AppTec's largest and fastest-growing market. Revenue from the U.S. climbed to 22.28 billion yuan in the first half, up from 14.24 billion yuan a year earlier, and now accounts for approximately 77% of the company's total revenue.

Outlook and Regulatory Context

WuXi AppTec's management reiterated its full-year financial guidance, projecting revenue between 51.3 billion and 53.0 billion yuan. This represents expected year-over-year revenue growth of 18% to 22% from continuing operations.

The company also addressed its recent inclusion on the U.S. Department of Defense's Section 1260H list. Chief Executive Li Ge stated that the designation was "not supported by facts or law" and affirmed that the company would continue to defend its interests, expressing confidence in its ongoing legal challenge.